Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG

ObjectivesMyasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspect...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ open Ročník 13; číslo 1; s. e066445
Hlavní autoři: Dewilde, Sarah, Philips, Glenn, Paci, Sandra, Beauchamp, Jon, Chiroli, Silvia, Quinn, Casey, Day, Laura, Larkin, Mark, Palace, Jacqueline, Berrih-Aknin, Sonia, Claeys, Kristl G, Muppidi, Srikanth, Mantegazza, Renato, Saccà, Francesco, Meisel, Andreas, Bassez, Guillaume, Murai, Hiroyuki, Janssen, MF
Médium: Journal Article
Jazyk:angličtina
Vydáno: England British Medical Journal Publishing Group 31.01.2023
BMJ Publishing Group LTD
BMJ Publishing Group
Edice:Original research
Témata:
Activities of Daily Living
Adult
Adult neurology
Data collection
Female
Humans
Male
Mental depression
Middle Aged
Myasthenia Gravis
Neurology
Neuromuscular disease
Patient Reported Outcome Measures
Patients
Prospective Studies
Quality of Life
Questionnaires
United Kingdom > UK
Adult neurology
Neuromuscular disease
NEUROLOGY
ISSN:2044-6055, 2044-6055
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:ObjectivesMyasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspective of the patient.DesignProspective, observational, digital, longitudinal real-world study.SettingAdult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG.Outcome measuresData was collected using the following general and disease-specific patient-reported outcome measurements: EuroQol 5 Domains Health-Related Quality of Life Questionnaire (EQ-5D-5L), Myasthenia Gravis Activities of Daily Living (MG-ADL), Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r), Hospital Anxiety and Depression Scale (HADS) and Health Utilities Index III (HUI3). Patients were categorised by their self-assessed Myasthenia Gravis Foundation of America (MGFA) class (I–V).ResultsBaseline results of 841 participants (mean age 47 years, 70% women) are reported . The distribution across the MGFA classes was: 13.9%, 31.0%, 38.1%, 15.5% and 1.6% for classes I–V. The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision. The mean total MG-ADL Score was positively associated with increasing MGFA classes: 2.7, 4.4, 6.3 and 8.4 for MGFA classes I–IV. Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV.ConclusionsMG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.
Bibliografie:Original research
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2022-066445